Sentinel node radiotracer shows early promise:
This article was originally published in Clinica
A potentially new radiotracer for identifying lymphatic tissue during a sentinel node biopsy procedure has produced promising results in a preclinical trial. 99mTc(DTPA)-mannosyl-dextran, developed by a team from the University of California, San Diego, could dramatically enhance the diagnostic performance of the sentinel node technique in melanoma, breast and other cancers, says US firm, Neoprobe, of Dublin, Ohio. Neoprobe holds a licence option for the compound, which exhibited rapid injection site clearance and little accumulation in nodes other than the sentinel one, according to the trial, published in The Journal of Nuclear Medicine (June).
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.